Table 4.

Treatment characteristics and response at 6 mo

	Revlimid, 5 mg (n = 26)	Revlimid, 25 mg (n = 34)	P
Percentage with no progression at 6 mo	50% (n = 13)	44% (n = 15)
Reason for stopping lenalidomide
Toxicity	11.5% (n = 3)	17.5% (n = 6)
Progression of PSA ≥25%	27% (n = 7)	15% (n = 5)
Progression of scans	11.5% (n = 3)	23.5% (n = 8)
No PSA progression (in all patients)	50% (n = 13)	56% (n = 19)
Negative PSA slope at 6 mo	38% (n = 10)	38% (n = 13)
Mean PSA slope change (range, 95% CI)	−0.033 (−0.11 to 0.04)	−0.172 (−0.24 to −0.11)	0.005
Mean (range, 95% CI) steady state (at 2 mo), lenalidomide-plasma concentration (ng/mL)	12.67 (6.1–19.2)	65.14 (24.3–106.0)	0.01